<DOC>
	<DOCNO>NCT01040156</DOCNO>
	<brief_summary>Pediatric patient high risk acquire mycotic infection follow allogeneic bone marrow transplantation . In present retrospective analysis ass safety efficacy different regimen antimycotic prophylaxis .</brief_summary>
	<brief_title>Antimycotic Prophylaxis Pediatric Patients Following Allogeneic Stem Cell Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<criteria>Pediatric patient age 18 year Pediatric patient HSCT treat caspofungin Pediatric patient HSCT treat liposomal amphotericin Pediatric patient uncontrolled hematological malignancy Pediatric patient IFI start HSCT</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>